Amnavero.
← Research directory

Research profile

CJC-1295

CJC-1295 mimics growth hormone-releasing hormone. The published study used a long-acting version.

  • Early human biomarker studies
  • Evaluation only
Amnavero CJC-1295 research vial concept packaging
Amnavero CJC-1295
Concept packaging

What the research found

In early studies in healthy adults, one administration of the long-acting compound increased mean growth hormone levels for at least six days. Mean IGF-1 also increased.

What remains uncertain

Changes in hormone levels leave clinical benefit and long-term safety unanswered. The specific formulation matters when comparing results.